U.S.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a co

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		10761459		
Filing Date		2004-01-22		
First Named Inventor   Ian M		f. Penn		
Art Unit		3738		
Examiner Name	Vy Q	Bui		
Attorney Docket Number		213202-00493		

U.S.PATENTS									Remove		
Examiner Initial*	Cite No	Patent Number	nber Kind Issue Date Name of Patentee or Applicant Releval				ines where				
	1	5843117	A	1998-1	2-01	Alt et al.					
	2	5397355	A	1995-0	3-14	Marin et al.					
	3	5019090		1991-0	5-28	Pinchuk					
If you wis	h to a	dd additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUBL	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	tion	Name of Pate of cited Docu	entee or Applicant iment	Relev		ines where es or Relev	
	1										
If you wis	h to a	ı dd additional U.S. Publi	shed Ap	plication	citation	n information p	olease click the Ad	d buttor	n. Add		
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>				Name of Patente Applicant of cited Document	e or	where Rele	or Relevant	Тs
	1	0 679 372	EP		A2	1995-11-02	Advanced Cardiovascular Sys Inc.	stems,			

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10761459
Filing Date		2004-01-22
First Named Inventor	lan M	I. Penn
Art Unit		3738
Examiner Name	Vy Q	Bui
Attorney Docket Numb	er	213202-00493

	2	0 364 787	EP	A1	1990-04-25	Expandable Grafts Partnership			
	3	95/26695	wo	A2	1995-10-12	Lau et al.			
	4	0 732 088	EP	A2	1996-09-18	Advanced Cardiovascular Systems, Inc.			
If you wis	h to ac	d additional Foreign Pa	atent Document	citation	information pl	ease click the Add buttor			
			NON-PATER	IT LITE	RATURE DO	CUMENTS	Remove		
Examiner linitials* Cite include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposishum, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.									
	1	SECOND THORAXCENTER COURSE ON CORONARY STENTING, Rotterdam, the Netherlands, December 13-16, 1995							
	JOHN H.K. VOGEL, M.D. and SPENCER B. KING III, M.D. (Editors), The Practice of Interventional Cardiology, Second Edition, chapter 29 - Sternis For Ballout and Restenosis, pp. 301-306, 1993								
	3 Declaration of Jerome Segal, M.D., February 2, 2006								
	4	LPL Systems Inc. System 2000 Stiert Cultor from the LPL Systems, Inc web page at <a href="http://www.lpssystems.com/stert_outer-html-retrieved-on-11/08/2004">http://www.lpssystems.com/stert_outer-html-retrieved-on-11/08/2004</a>							
	5	LPL Systems, Inc Invoice, Quote No. 11295, Date 11/29/95							
	6 Declaration of Charles A. Taylor, November 9, 2004								

	Application Number		10761459	
	Application Number		10/61439	
INFORMATION DIGGS COURT	Filing Date		2004-01-22	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor lan M		f. Penn	
(Not for submission under 37 CFR 1.99)	Art Unit		3738	
,	Examiner Name Vy Q		. Bui	
	Attorney Docket Numb	er	213202-00493	

7	Declaration of Richard J. Saunders Regarding European Patent EP 1 066 804, January 28, 2006	

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kint Code of USPTO Patent Documents at invenUSPTO\_GDI/ or MPEP 901.04. \* Enter of thice that issued the document, by the involved ow (WIPO Standard ST3.). \* For Suppresse patent counters, the noticeation of the year of the region of the Emperor many precede the sent annual replication of the part document.

\*\*Ind of counter by the appropriate symbols as endicated on the document under WIPO Standard ST1.6 if possole, \*\*Applicant is to place a check mark here if Emploit languages translation is attached.\*\*

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10761459
Filing Date		2004-01-22
First Named Inventor Ian M		. Penn
Art Unit		3738
Examiner Name	Vy Q	Bui
Attorney Docket Number		213202-00493

#### CERTIFICATION STATEMENT

Please see	37	CFR	1.97	and f	1 98 t	make the	annronriat	e selection(s):

	That each item of information contained in the information disclosure statement was first cited in any communication
	from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
_	information disclosure statement. See 37 CFR 1 97(eV1)

#### ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, not not information contained in the information disclosure statement was known to any individual designated in 37 CFR 1/5(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/9/(c)(d).

Fee set forth in 37 CFR 1,17 (p) has been submitted herewith.

.7 None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Richard P. Bauer/	Date (YYYY-MM-DD)	2006-09-21
Name/Print	Richard P. Bauer	Registration Number	31588

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenan's Afford, U.S. Department of Commence, P. 0. Bot 1450, Alexandria, V.3.251.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, V.3.231.1450.

### Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicide is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually the principal purpose and for examines your submission, which may visually intermediate or of extended now about the principal purpose.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuint to 5 U.S.C. 552a(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs and of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.